📇 Rhumatologue · ST CLOUD · (92) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
28 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
35
35 articles ont été cités au moins 35fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
4 405
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
186
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
77
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Institut Curie
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Effect of Breast Surgery on Quality of Life in BRCA Mutation Carriers With Invasive Breast Cancer: A CANTO Database Study
2025ArticleClinical Breast Cancer
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study
2025ArticleBritish Journal of Cancer
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer
2025Articlenpj Breast Cancer
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial
2025ArticleLancet Oncology
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2024ArticleLancet Oncology
Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy
2024ArticleJournal of Translational Medicine
Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer
2024ArticleEuropean Journal of Nuclear Medicine and Molecular Imaging
Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model
2024ArticleJNCI: Journal of the National Cancer Institute
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CLCC RENE HUGUENIN INSTITUT CURIE
35 R DAILLY, 92210 ST CLOUD
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Lancet. Oncology · 2021
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
PURPOSEAdverse effects of breast cancer treatment can negatively affect survivors’ work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact of treatment and related sequelae on employment.METHODSWe used a French prospective clinical cohort of patients with stage I-III breast cancer including 1,874 women who were working and ≥ 5 years younger than legal retirement age (≤ 57 years) at breast cancer diagnosis. Our outcome was nonreturn to work (non-RTW) 2 years after diagnosis. Independent variables included treatment characteristics as well as toxicities (Common Toxicity Criteria Adverse Events [CTCAE] v4) and PROs (European Organization for Research and Treatment of Cancer [EORTC] Quality of life Questionnaires, Breast cancer module [QLQ-BR23] and Fatigue module [QLQ-FA12], Hospital Anxiety and Depression Scale) collected 1 year after diagnosis. Logistic regression models assessed correlates of non-RTW, adjusting for age, stage, comorbidities, and socioeconomic covariates.RESULTSTwo years after diagnosis, 21% of patients had not returned to work. Odds of non-RTW were significantly increased among patients treated with combinations of chemotherapy and trastuzumab (odds ratio [OR] v chemotherapy-hormonotherapy: for chemotherapy-trastuzumab, 2.01; 95% CI, 1.18 to 3.44; for chemotherapy-trastuzumab-hormonotherapy, 1.62; 95% CI, 1.10 to 2.41). Other significant associations with non-RTW included grade ≥ 3 CTCAE toxicities (OR v no, 1.59; 95% CI, 1.15 to 2.18), arm morbidity (OR v no, 1.59; 95% CI, 1.19 to 2.13), anxiety (OR v no, 1.47; 95% CI, 1.02 to 2.11), and depression (OR v no, 2.29; 95% CI, 1.34 to 3.91).CONCLUSIONReceipt of systemic therapy combinations including trastuzumab was associated with increased odds of non-RTW. Likelihood of unemployment was also higher among patients who reported severe physical and psychological symptoms. This comprehensive study identifies potentially vulnerable patients and warrants supportive interventional strategies to facilitate their RTW.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of the National Cancer Institute · 2025 · Clinical Trial
Presti D, Di Meglio A, Havas J, Pagliuca M, et al.
European journal of nuclear medicine and molecular imaging · 2025 · Journal Article
Seban RD, Champion L, De Moura A, Lerebours F, et al.
The Lancet. Oncology · 2024 · Journal Article
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, et al.
Journal of translational medicine · 2024 · Journal Article
Bertucci F, Guille A, Lerebours F, Ceccarelli M, et al.
Journal of translational medicine · 2024 · Journal Article
Bertucci F, Lerebours F, Ceccarelli M, Guille A, et al.
Cancer research communications · 2024 · Journal Article
De Schepper M, Nguyen HL, Richard F, Rosias L, et al.
Cancer medicine · 2023 · Journal Article
Ruiz de Azua G, Kousignian I, Vaz-Luis I, Di Meglio A, et al.
Cancers · 2022 · Journal Article
Grandal B, Aljehani A, Dumas E, Daoud E, et al.
Breast cancer research and treatment · 2022 · Journal Article
Corbaux P, Lardy-Cleaud A, Alexandre M, Fontanilles M, et al.
Current oncology (Toronto, Ont.) · 2021 · Journal Article
Caumette E, Vaz-Luis I, Pinto S, Havas J, et al.
Frontiers in oncology · 2021 · Journal Article
Hours A, Toussaint A, De Castelbajac V, Sautter C, et al.
The Lancet. Oncology · 2021 · Clinical Trial, Phase II
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, et al.
Psycho-oncology · 2021 · Journal Article
Hardy-Leger I, Charles C, Lange M, Joly F, et al.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020 · Journal Article
Lange M, Hardy-Léger I, Licaj I, Pistilli B, et al.
Clinical breast cancer · 2025 · Journal Article
Mahiou K, Bonneau C, Coutant C, Martin AL, et al.
Journal of the National Cancer Institute · 2023 · Journal Article
Balazard F, Bertaut A, Bordet É, Mulard S, et al.
Cancer · 2022 · Journal Article
Soldato D, Havas J, Crane TE, Presti D, et al.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · Journal Article
Lapidari P, Lustberg MB, Havas J, Pagliuca M, et al.
British journal of cancer · 2026 · Journal Article
Ruiz de Azua G, Licaj I, Pinto S, Havas J, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · Journal Article
Dumas A, Vaz Luis I, Bovagnet T, El Mouhebb M, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Journal Article
Dieras V, Curigliano G, Martin M, Lerebours F, et al.
The Lancet. Oncology · 2025 · Journal Article
Bonnefoi H, Lerebours F, Pulido M, Arnedos M, et al.
British journal of cancer · 2022 · Journal Article
Baker JL, Di Meglio A, Gbenou AS, El Mouhebb M, et al.
PloS one · 2020 · Journal Article
Hamy AS, Darrigues L, Laas E, De Croze D, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · Journal Article
Vaz-Luis I, Di Meglio A, Havas J, El-Mouhebb M, et al.
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study
Abstract Background Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed
Additional file 7 of Mutational landscape of inflammatory breast cancer
Additional file 7: Figure S1. Tumor mutational burden TMB) in IBCs and non-IBCs. A/ Violin plots showing the distribution of the TMB in IBCs and non-IBCs. The p-value is for the Wilcoxon test. B/ Similar to A/ but per mo
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer
Abstract Background Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer. Using a custom-made breast cancer gene sequencing panel, we investigated somatic mutations in IBC to better under
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer
Abstract Background Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer. Using a custom-made breast cancer gene sequencing panel, we investigated somatic mutations in IBC to better under
Additional file 1 of Mutational landscape of inflammatory breast cancer
Additional file 1: Table S1. Clinicopathological characteristics of patients and samples.
Mutational landscape of inflammatory breast cancer
Abstract Background Inflammatory breast cancer (IBC) is the most pro-metastatic form of BC. Better understanding of its enigmatic pathophysiology is crucial. We report here the largest whole-exome sequencing (WES) study
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · Journal Article
Di Meglio A, Havas J, Gbenou AS, Martin E, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · Journal Article
Vaz-Luis I, Di Meglio A, Havas J, El-Mouhebb M, et al.
Breast (Edinburgh, Scotland) · 2021 · Journal Article
Lapidari P, Gbenou A, Havas J, Martin E, et al.
Frontiers in oncology · 2020 · Journal Article
Bertucci A, Bertucci F, Zemmour C, Lerebours F, et al.